| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fcb093a174d5182b5854b704cb09354
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f63eecb83c17f70b314aebe73e0f023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc98acc7b25db1fb35032bf5d2e2fd72 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2008-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0336de4b591e27562b0b42fe3333fe56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_796dc60b7028a6e757404eb93f639df8 |
| publicationDate |
2014-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8846386-B2 |
| titleOfInvention |
sVEGFR-2 and its role in lymphangiogenesis modulation |
| abstract |
Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11702660-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11096956-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10538764-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10696969-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10683503-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10941405-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10913947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11083745-B2 |
| priorityDate |
2007-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |